No Data
No Data
Bell Potter Says This ASX Biotech Stock Could Rocket 80%
Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares could have huge upside potential.
Paradigm Biopharmaceuticals Price Target Cut 66% to A$0.47/Share by Bell Potter
Paradigm Biopharmaceuticals Price Target Cut 66% to A$0.47/Share by Bell Potter
Paradigm Biopharma's Injectable Pentosan Polysulfate Sodium Trial Reaches Endpoint
Paradigm Biopharma's (ASX:PAR) phase 2 clinical trial showed that pain eased in patients while using the injectable pentosan polysulfate sodium after the trial reached the primary endpoint. The trial
Paradigm Biopharmaceuticals Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023; Shares Rally 9%
Paradigm Biopharmaceuticals (ASX:PAR) secured a AU$7.4 million rebate from the Australian government's research and development tax incentive scheme for the fiscal year ended June 30, 2023. The scheme
Here's a 33c ASX Stock That Could Have the Potential to Reach $1+
At the small side of the market there are opportunities to generate incredible returns.
Paradigm Biopharmaceuticals Opens Retail Entitlement Offer
Paradigm Biopharmaceuticals (ASX:PAR) opened its 1-for-10 retail entitlement offer priced at AU$0.43 per share. The shares come with 3-for-4 options that can be exercised at AU$0.65 apiece and expire
No Data
71841853 : i took my gain today